ArticleFrontiers in pediatrics2025
Clinical presentation and early predictors of progression to dilated cardiomyopathy in children with acute myocarditis.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to describe the characteristics and outcomes of acute myocarditis (AM) patients while seeking accessible and valid early predictors for the development of dilated cardiomyopathy (DCM). Methods: We conducted a retrospective evaluation of 136 consecutive AM patients admitted to our hospital. The patients were categorized into two groups according to their left ventricular ejection fraction (LVEF) at presentation: those with an impaired LVEF of ≤55% and those with a normal LVEF of >55%. Multivariate logistic regression analyses were conducted to identify early predictors of DCM. Results: The median age of the study participants was 10.35 years (5.60-14.70), and most of the participants (66.91%) were males. Thirty-eight (27.94%) patients had an LVEF of ≤55%. Compared with those with an LVEF >55%, patients with an LVEF ≤55% presented significantly elevated levels of cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), as well as more pronounced clinical manifestations, including a greater prevalence of fulminant myocarditis, New York Heart Association (NYHA) class II-IV, abnormal electrocardiogram results, and enlargement of the left ventricle on echocardiography. Univariate analysis revealed that patients with an LVEF of ≤55% had an increased risk of poor outcomes and DCM development. These patients faced the greatest likelihood of death and heart transplantation within the first year following discharge. During short-term follow-up, 15.44% of the children with AM progressed to DCM. According to the multivariable analysis, a higher baseline LV end-diastolic diameter z score (LVEDD z-score) independently predicted this progression (odds ratio [OR], 2.685; 95% confidence interval [CI], 1.232-5.851; Conclusions: Patients with AM and LVEF ≤55% had a more severe clinical course, higher rates of poor outcomes, and increased risk of DCM progression. Moreover, this subgroup was at the greatest risk for death and heart transplant within the first year post-discharge. During short-term follow-up, 15.44% of the children diagnosed with AM progressed to DCM, with a higher baseline LVEDD z-score identified as a potential early predictor for this progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.